• NEWS . 21 Sep 2020
  • Secondary prevention combination therapy with beta-blocker and statin reduced MACE in ACS patients

  • A combination therapy of beta-blocker and statin more effectively lowered the risk of developing major adverse cardiovascular event (MACE) in patients with acute coronary syndrome (ACS), compared with a beta-blocker or statin alone. This is according to a recent study.

    In the study, the 636 ACS patients included (66.8% men; mean age, 60.42±9.83 years) were assigned one of four treatment strategies: no therapy (n=139), including those who never used or inconsistently used beta-blocker and statin; beta-blocker monotherapy (n=71); statin monotherapy (n=149); and co-therapy (n=277). 

    Results showed that, compared with the no therapy group, the statin monotherapy group and co-therapy group had a lower risk of MACE (statin monotherapy group: adjusted hazard ratio [HR], 0.35, 95% confidence interval [CI], 0.20–0.60; p<0.001; co-therapy group: adjusted HR, 0.16, 95% CI, 0.09–0.28; p<0.001). Finally, in a subgroup analysis, co-therapy significantly reduced the risks of MACE occurrences in ACS patients compared with beta-blocker monotherapy and statin monotherapy (beta-blocker monotherapy group: adjusted HR, 0.28, 95% CI, 0.13–0.59; p=0.001; statin monotherapy group: adjusted HR, 0.54, 95% CI, 0.29–0.98; p=0.044).

    Reference:
    Zhu L, et al. Effects of a secondary prevention combination therapy with beta-blocker and statin on major adverse cardiovascular events in acute coronary syndrome patients. Med Sci Monit 2020;26:e925114.